QQQ

DIA

SPY

TLT

GLD

BTC/USD

QQQ

DIA

SPY

TLT

GLD

BTC/USD

Range

3.97 - 4.65

Vol / Avg.

6.6M/1.7M

Div / Yield

-

52 Wk

3.35 - 13.81

Mkt Cap

75.3M

Payout Ratio

-

Open

4.19

P/E

-

EPS

-0.25

Shares

17.3M

Outstanding

17.3M

Total Float

15.8M

Analyst Ratings

68 Biggest Movers From Wednesday

Benzinga - 1 day ago

Ocuphire Pharma Option Alert: Dec 17 $7.5 Calls Sweep (6) near the Ask: 1000 @ $0.3 vs 0 OI; Ref=$4.9797

Benzinga - 3 days ago

Ocuphire Pharma shares are trading higher after HC Wainwright & Co initiated coverage on the stock with a Buy rating and a $26 price target. The company yesterday announced the first subjects have been enrolled in the MIRA-3 Phase 3 pivotal trial evaluating Nyxol Eye Drops in the reversal of pharmacologically-induced mydriasis.

Benzinga - 3 days ago

HC Wainwright & Co. Initiates Coverage On Ocuphire Pharma with Buy Rating, Announces Price Target of $26

Benzinga - 3 days ago

Ocuphire Announces Enrollment Of First Patients In Second Phase 3 Pivotal Trial (MIRA-3) For Nyxol In Reversal of Mydriasis

Benzinga - 4 days ago

Ocuphire Pharma Q3 EPS $(0.25) Up From $(0.33) YoY

Benzinga - Nov 12, 2021, 7:13AM

Ocuphire Invited To Present Clinical Data On Nyxol And APX3330 At American Academy Of Ophthalmology 2021 Annual Meeting And Eyecelerator/AAO Meeting

Benzinga - Nov 1, 2021, 9:31AM

Ocuphire Announces Publications Featuring The Ref-1 Protein, A Transcription Factor Regulator, As A Novel Therapeutic Target For The Treatment Of Neovascular Retinal Diseases

Benzinga - Oct 7, 2021, 7:03AM

Ocuphire Pharma To Present Data On Phase 2b Trial For APX3330 For Retina At Ophthalmology Innovation Summit Retina@ASRS Innovation Company Showcase Oct. 7 At 10:16 a.m. EDT, Diabetic Symposium Oct. 9 9:51 a.m. EDT

Benzinga - Oct 1, 2021, 8:51AM

From BZ's Small Cap Healthcare Conference: Ocuphire Pharma Founder & CEO, Mina Sooch Says Co Will Create $700 Million In Revenues Around 2023

Benzinga - Sep 29, 2021, 10:00AM

From BZ's Small Cap Healthcare Conference: Ocuphire Pharma Founder & CEO, Mina Sooch Begin Presenting

Benzinga - Sep 29, 2021, 9:51AM

Ocuphire Pharma Q2 EPS $(0.52) Down From $(0.43) YoY

Benzinga - Aug 12, 2021, 7:32AM

Ocuphire Shares Spike Higher After Hours; Two Presentations from Conferences in July Posted on Reuters Just Ahead of the Close

Benzinga - Aug 5, 2021, 4:49PM

Ocuphire Highlights Publication In The Journal Of Cellular Signaling Featuring Its Oral Ref-1 Inhibitor APX3330 In Phase 2 Trial For The Treatment Of Retinal Disease

Benzinga - Jul 22, 2021, 8:01AM

Ocuphire Says Selected To Present At Multiple Ophthalmic Conferences In July

Benzinga - Jul 13, 2021, 9:06AM

Occuphire Pharma Shares Move Higher; Hearing Ray Blanco Sets Stock As New Buy

Benzinga - Jul 7, 2021, 1:27PM

load more

Sector: Health Care.Industry: Pharmaceuticals

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.

Earnings

Q3 2021		Est.		Actual		Surprise
EPS		-0.360		-0.250		0.1100
REV				489.000K

Analyst Ratings

Date	Analyst Firm	Analyst Name	Action	Rating	Action Price	Prior Price	Target

Ocuphire Pharma Questions & Anwsers

Q

How do I buy Ocuphire Pharma (OCUP) stock?

A

You can purchase shares of Ocuphire Pharma (NASDAQ: OCUP) through any online brokerage.

View our list of the best stock brokerages.

Q

Who are Ocuphire Pharma's (OCUP) competitors?

A

Other companies in Ocuphire Pharma’s space includes: Iterum Therapeutics (NASDAQ:ITRM), Cocrystal Pharma (NASDAQ:COCP), Onconova Therapeutics (NASDAQ:ONTX), Universe Pharmaceuticals (NASDAQ:UPC) and Jaguar Health (NASDAQ:JAGX).

Q

What is the target price for Ocuphire Pharma (OCUP) stock?

A

The latest price target for Ocuphire Pharma (NASDAQ: OCUP) was reported by HC Wainwright & Co. on November 24, 2021. The analyst firm set a price target for 26.00 expecting OCUP to rise to within 12 months (a possible 497.70% upside). 5 analyst firms have reported ratings in the last year.

Q

Current Stock Price for Ocuphire Pharma (OCUP)?

A

The stock price for Ocuphire Pharma (NASDAQ: OCUP) is $4.35 last updated Fri Nov 26 2021 18:00:04 GMT+0000 (Coordinated Universal Time).

Q

Does Ocuphire Pharma (OCUP) pay a dividend?

A

There are no upcoming dividends for Ocuphire Pharma.

Q

When is Ocuphire Pharma (NASDAQ:OCUP) reporting earnings?

A

Ocuphire Pharma’s $Q3 earnings are confirmed for after-market on November 12, 2021.

Q

Is Ocuphire Pharma (OCUP) going to split?

A

There is no upcoming split for Ocuphire Pharma.

Q

What sector and industry does Ocuphire Pharma (OCUP) operate in?

A

Ocuphire Pharma is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.